

1 Transient peripheral blood transcriptomic response to ketamine treatment 2 in children with ADNP syndrome 3

4 Ariela S. Buxbaum Grice^{1,2,3}, Laura Sloofman^{1,2,3}, Tess Levy^{1,2}, Hannah Walker^{1,2}, Gauri Ganesh^{1,2,3}, Miguel
5 Rodriguez de los Santos^{1,2,3}, Pardis Armini^{1,2,3}, Joseph D. Buxbaum^{1,2,3,4}, Alexander Kolevzon^{1,2,4,5}, Ana
6 Kostic^{1,2}, Michael S. Breen^{1,2,3,4}

7 8 Affiliations:

- 9 1. Seaver Autism Center for Research and Treatment, Icahn School of Medicine at Mount Sinai, New
10 York, NY, USA
- 11 2. Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
- 12 3. Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York,
13 NY, USA.
- 14 4. Mindich Child Health and Development Institute, Icahn School of Medicine at Mount Sinai, New York,
15 NY, USA.
- 16 5. Department of Pediatrics, Icahn School of Medicine at Mount Sinai, New York, NY, USA

ABSTRACT

Activity-dependent neuroprotective protein (ADNP) syndrome is a rare neurodevelopmental disorder resulting in intellectual disability, developmental delay and autism spectrum disorder (ASD) and is due to mutations in the *ADNP* gene. Ketamine treatment has emerged as a promising therapeutic option for ADNP syndrome, showing safety and apparent behavioral improvements in a first open label study. However, the molecular perturbations induced by ketamine remain poorly understood. Here, we investigated the longitudinal effect of ketamine on the blood transcriptome of 10 individuals with ADNP syndrome. Transcriptomic profiling was performed before and at multiple time points after a single low-dose intravenous ketamine infusion (0.5mg/kg). We show that ketamine triggers immediate and profound gene expression alterations, with specific enrichment of monocyte-related expression patterns. These acute alterations encompass diverse signaling pathways and co-expression networks, implicating up-regulation of immune and inflammatory-related processes and down-regulation of RNA processing mechanisms and metabolism. Notably, these changes exhibit a transient nature, returning to baseline levels 24 hours to 1 week after treatment. These findings enhance our understanding of ketamine's molecular effects and lay the groundwork for further research elucidating its specific cellular and molecular targets. Moreover, they contribute to the development of therapeutic strategies for ADNP syndrome and potentially, ASD more broadly.

10 INTRODUCTION

11
12 ADNP syndrome (also known as Helsmoortel-Van Der Aa Syndrome) is a monogenic neurodevelopmental disorder
13 caused by mutations in activity-dependent neuroprotective protein (*ADNP*). ADNP syndrome is clinically characterized
14 by global developmental delay, intellectual disability (ID), and behavioral disorders including autism spectrum disorder
15 (ASD). Although pathogenic mutations in *ADNP* account for ~0.2% of ASD cases (Gozes, 2020; Siper, et al., 2021;
16 Helsmoortel, et al., 2014), the clinical profile of ADNP syndrome is distinct from individuals with idiopathic ASD
17 (Arnett, et al., 2018); Siper 2021. ADNP syndrome can manifest across an array of physical and psychiatric domains,
18 including motor and language delays, hypotonia, congenital heart disease, sensory reactivity, and additional behavioral
19 manifestations (Helsmoortel, et al., 2014; Siper, et al., 2021). Most infants and children with ADNP syndrome have some
20 form of feeding difficulty, largely caused by dysfunctions in oral motor control (NIH, 2021); apraxia and other motor
21 disorders (Van Dijck, et al., 2019).

22
23 ADNP is located on chromosome 20 at q13.13 and encodes for a protein that is crucial for brain function and
24 neurodevelopment (Karmon, et al., 2022; Gozes, 2020). ADNP plays a role in modulating chromatin structure and
25 maintaining gene transcription and neuronal differentiation. *ADNP* interacts directly with two microtubule end-binding
26 proteins (EB1 & EB3) and *ADNP* allelic mutations perturb this interaction (Gozes, et al., 2015; Ivashko-Pachima, et al.,
27 2017). Most pathogenic mutations in *ADNP* involve *de novo* premature termination codons (Chen, et al., 2023) and a loss
28 of function mechanism is therefore assumed. However, it has been shown that mutant transcripts are expressed, consistent
29 with most of the protein being coded from the terminal exon (Gozes, 2020, Breen et al., 2020). The position of the
30 mutation within the *ADNP* coding sequence results in two very different DNA methylation patterns in blood, which is also
31 not consistent with a simple haploinsufficiency mechanism (Breen et al., 2020).

32
33 While there are currently no specific therapeutic strategies for ADNP syndrome, there are studies underway using model
34 systems to assess the efficacy of some targeted therapies. The most extensive research has been on a peptide called NAP,
35 derived from ADNP, where pre-clinical studies in mice suggest a potential for NAP to be protective against damaging
36 mutations in ADNP, but clinical data have not been generated (Gozes, 2020). More recently, ketamine treatment has been
37 proposed as a potential therapeutic for ADNP syndrome. Ketamine is an NMDA receptor agonist with pro-glutamatergic
38 activity, approved for anesthetic purposes and as a therapeutic intervention for treatment-resistant depression (Jia & Hong,
39 2014; Acevedo-Diaz, et al., 2020). Ketamine's effects – particularly its adverse events – are generally transient and, while
40 there has been concern about a potential neurotoxic effect of ketamine administered at high doses, (40mg/kg), subclinical
41 and subanesthetic are well tolerated and may, in fact, have neuroprotective effects (Jia & Hong, 2014; Acevedo-Diaz, et
42 al., 2020). To this end, the first open-label safety and preliminary efficacy trial of intravenous ketamine was carried out in
43 ADNP syndrome (Kolevzon, et al., 2022). This study was the first of its class for ADNP syndrome and provides
44 preliminary clinical evidence for improvements in key domains of social communication, attention deficient and
45 hyperactivity, restricted and repetitive behaviors, speech, and activities of daily living.

46
47 To build upon these recent efforts, we present complimentary molecular data from individuals with ADNP syndrome who
48 participated in the ketamine trial (Kolevzon, et al., 2022). The primary goal of the current investigation was to examine
49 the transcriptomic response to ketamine treatment in blood and in the immune milieu and to dissect its effects on ADNP-
50 related biology. To do so, we performed a comparative RNA-sequencing analysis of peripheral blood immune cells from
51 10 individuals with ADNP syndrome before and after a single intravenous infusion of ketamine (0.5mg/kg). A multi-step
52 analytical approach was used that specifically sought to (1) identify individual genes that differ in their response to
53 ketamine, (2) replicate ketamine-induced gene expression profiles in independent transcriptomic studies, and (3) to
54 identify the ketamine-regulated gene networks, thereby providing a functional and mechanistic readout for ketamine
55 response.

METHODS

Study design

Peripheral blood biospecimens were collected at the following timepoints: (1) during a screening period within the 4 weeks preceding a baseline visit; (2) immediately following a single low-dose administration of ketamine (0.5mg/kg); and (3) during clinic visits for safety, clinical outcome, and biomarker assessments at day 1, week 1, 2, and 4.

RNA-sequencing data pre-processing and quality control

Blood was collected in PAXgene tubes and RNA extraction was performed using the PAXgene Blood RNA kit (Qiagen). All samples submitted for sequencing had RNA integrity numbers (RIN) of ≥ 8 . RNA-sequencing (RNAseq) was performed by the New York Genome Center in New York, NY, USA. The mRNA TruSeq Stranded kit (Illumina) was used for library preparation and RNA sequencing was run using the NovaSeq system (Illumina) and paired-end chemistry (2x100bp). Notably, PAXgene tubes enable RNA isolation and transcriptome sequencing of peripheral blood leukocytes, which was referred to as the peripheral blood transcriptome in the current study. Sequenced raw RNA reads were aligned to hg38 Ensembl using STAR (Dobin, et al., 2013). RNA quality control was performed using RSeQC (Wang, et al., 2012) and Picard (Broad Institute, 2019) to quantify percent GC, percent duplicates, gene body coverage, and library complexity, as well as to perform unsupervised clustering, and to mark duplicate reads. Next, gene expression was quantified using featureCounts (Liao, et al., 2014). Subsequently, the raw gene expression matrix was filtered to include only genes that were expressed across one-third of the samples in the cohort and normalized using VOOM (Robinson, et al., 2010), resulting in a resulting in a filtered and normalized expression matrix of 17,218 genes.

Outlier identification and removal

Using the high-quality mapped bam files obtained, we employed the samtools mpileup function to verify the presence of the reported mutation in all individuals (*see details below*). This approach allowed us to confirm the mutation consistently across multiple timepoints for each participant, ensuring reliable validation. We observed two participants (donor IDs: 1668.201, post-infusion timepoint & 1628.201, week 4 timepoint) in whom the expected mutation could not be quantified at one timepoint, differing from the other timepoints. As a result, these two samples were excluded from further analysis since their ADNP mutations could not be accurately quantified and deviated from the remaining repeated measures.

Subsequently, a principal component analysis was conducted on the remaining samples to identify expression outliers that exceeded two standard deviations from the grand mean. Consequently, one sample was considered an outlier and eliminated from the analysis (donor ID: 1329.202, post-infusion timepoint), retaining a total of 51 participants for further analysis.

Querying ADNP allele-specific expression

The fraction of mutant vs. healthy alleles for the pathogenic ADNP mutation associated with each sample was also quantified, to see whether ADNP allele-specific expression changes corresponded to ketamine treatment. Mapped BAM files from each sample were queried at the location of their associated ADNP mutation site using the mpileup function from Samtools (Danecek, et al., 2021). For samples with a single nucleotide mutation, just the location of the mutated nucleotide was queried; for samples with small deletions or insertions, a region of 10nt, encompassing the affected region, was queried. For mutations affecting two or more nucleotides, the percent reference was calculated as an average of the percent reference alleles across the affected range.

Cell type deconvolution

CIBERSORTx (<https://cibersortx.stanford.edu>) was used to perform cell type deconvolution. Cell fractions were imputed using LM22 as the signature matrix (Chen, et al., 2018). Because CIBERSORTx requires gene symbols (as opposed to, for example, EnsIDs), the genes in the unfiltered raw expression matrix were converted to HGNC gene symbols using biomaRt (Durinck, et al., 2005). In instances where two Ensembl IDs corresponded to the same HGNC symbol, the Ensembl ID with highest average expression was retained and the other removed. After conversion to gene symbols, the raw expression matrix contained 40,104 genes, and this matrix was used as the mixture file (without batch correction, and with quantile normalization disabled) for the CIBERSORTx analysis. A total of 15 immune cell types were estimated in this dataset and were subjected to a Dunnett's test using the DescTools (Signorell & et al, 2022) package to compare baseline cellular proportions (prior to ketamine administration) to subsequent timepoints in the trial.

Computing gene expression variance explained by technical and biological factors

To determine the best fit model equation for differential gene expression analysis, the variancePartition package (Hoffman & Schadt, 2016) was used. Variance partition analysis employs linear mixed models to quantify the effect of multiple covariates on overall gene expression variability — in this case, subject ID (since each subject was repeated across timepoints), subject sex, subject mutational class (Class I or Class II, see below), subject age, sample RIN, sample timepoint (defined as a factor with six levels: Baseline, Post-infusion, Day 1, Week 1, Week 2, Week 4) were modeled. Here mutational class refer to two classes defined by previously described differences in methylation changes: class I for individuals with mutations located outside a region between nucleotides 2000 and 2340 of the *ADNP* coding sequence and class II for individuals with mutations within this region, including the recurrent mutation p.Tyr719* (Breen et al., 2020; Bend et al., 2019).

Differential gene expression

Differential gene expression was performed on the VOOM-normalized matrix using the *limma* package (Ritchie, et al., 2015). Differential gene expression covaried for sex as a potential confounding variable as well as and donor as a repeated measure using the duplicateCorrelation() function from limma. A primary linear model was fit to contrast differences during the baseline timepoint versus five post-infusion timepoints (immediately post-infusion, day 1, week 1, week 2, week 4). Differentially expressed genes (DEGs) for each comparison were considered significant if they passed an Benjamini-Hochberg (BH) adjusted p-value threshold of <0.05.

To estimate the influence of varying cell type proportions on differential expression results, estimated cell type proportions, computed via CIBERSORTx, were individually added into each linear model as a covariate. Differential gene expression analysis was performed in the same way and using the same parameters and comparisons as for the original model design. After adjusting for cell type proportion, the number of significant differentially expressed genes from each timepoint relative to baseline (e.g., post-infusion, day 1, week 1, week 2, week 4) was ascertained. Then, the DEG list from our primary linear model (described above) was intersected with the resulting list of differentially expressed genes with cell type composition as a covariate. The percentage of original DEGs which were no longer significant was computed.

Querying cell-type specific enrichment of differential expression signatures

A two-step approach was used to dissect the potential impact of cell-type-specific effects on the bulk peripheral blood transcriptome signatures. First, we integrated estimated percent compositions of distinct cellular populations as covariates

79 into the differential expression model equation. This allowed us to compare the DEGs with and without incorporating cell
80 type adjustments, enabling a quantitative assessment of cellular influences on the differential expression comparison.
81 Second, to determine whether the differentially expressed genes or WGCNA modules were associated with any cell type,
82 target gene lists were tested for cell-type specific enrichment, as previously described (Breen et al., 2023). In brief, we
83 leveraged two existing scRNA-seq PBMC datasets, which were generated from two healthy donors. These datasets were
84 processed completely independently — in different laboratories, using different methodologies, and differing in the
85 number of sequenced cells. Both datasets are available as part of 10x Genomic’s publicly accessible data
86 (<https://www.10xgenomics.com/resources/datasets>). The first dataset, containing 33,227 PBMCs, was processed with Cell
87 Ranger 1.1.0, v.2 Chemistry (10x Genomics, 2016). The second, containing 67,272 PBMCs, was originally published by
88 the Zheng lab (Zheng, et al., 2017) and was processed with Cell Ranger 1.1.0, v.1 Chemistry (10x Genomics, 2016). Each
89 of the two single cell objects had already been filtered, normalized, scaled, and clustered, and the cell type identities
90 assigned.

91
92 For each PBMC dataset, cell-type specific enrichment analysis was performed for the following target gene sets:
93 significant DEGs from the Baseline vs. Post-infusion comparison and the Baseline vs. Day 1 comparison. First, the target
94 gene list was intersected with the associated PBMC expression matrix, to generate a PBMC expression matrix of just
95 genes in the target list. The moduleEigengenes function from the WGCNA package was then utilized to summarize each
96 cell’s expression of all the genes in the target list into a single “cell eigenvalue”. These per-cell eigenvalues were then
97 scaled and overlain onto the PBMC UMAP.

98 99 ***Replication of ketamine-induced transcriptional responses***

100
101 To replicate the ketamine-induced transcriptomic perturbations, we leveraged two independent transcriptome studies that
102 dissected the impact of ketamine on gene expression profiles (Ho, et al., 2019; Cathomas, et al. 2021).

103
104 Ho, et al., 2019 examined the effect of ketamine and its active metabolites on gene expression profiles using the HMC3
105 human microglial cell line. Here, ketamine, (2*R*,6*R*)-HMK, or (2*S*,6*S*)-HMK (400nM) were administered with or without
106 estradiol (E2; 0.1nM); these concentrations were chosen to emulate observed plasma concentrations seen during ketamine
107 treatment in human subjects (Zarate, et al., 2012; Ho, et al., 2019). To determine the extent of replication, raw FASTQ
108 files for six samples, including two replicates for ketamine and ketamine+E2 treatment, together with two replicates for
109 vehicle alone, were downloaded from GEO (GSE134782).

110
111 Cathomas, et al., 2022 explored the effect of intravenous ketamine (0.5mg/kg) on the peripheral blood transcriptome of 26
112 patients with treatment resistant depression and 21 healthy controls. Notably, blood samples and RNA extraction at
113 baseline and 24 hours post-treatment were ascertained and isolated using similar protocols in the current study. To
114 determine the extent of replication, raw FASTQ files for 42 samples (21 baseline and 21 post-ketamine treatment) were
115 downloaded from GEO (GSE185855).

116
117 Data pre-processing of all these two independent transcriptome studies was conducted as described above to ensure
118 accuracy and consistency. Following QC, RNA-sequencing mapping and counting, raw expression matrices were filtered
119 and normalized, and samples were clustered using PCA and MDs plots. To generate ketamine-induced transcriptional
120 responses from each of these studies, we performed the following analyses.

121
122 Due to sample size limitations for Ho et al., 2019, we computed log₂ fold-changes for each condition (ketamine and
123 ketamine + E2) relative to vehicle. Thus, a log₂ fold-change was generated for each gene specific to each treatment
124 condition. For Cathomas, et al., 2022, we used the following model in the limma R package : ($\sim 0 + Time + Group +$
125 Age), in which Time was a factor reflecting baseline or post-ketamine treatment, Age was the patient age, and Group was

26 a factor representing responder or non-responder status (responders were originally defined by a $\geq 50\%$ reduction of
27 baseline MADRS score). Donor as a repeated measure was also accounted for using *duplicateCorrelation()* from the
28 *limma R package*. Subsequently, \log_2 fold-changes were leveraged for comparative purposes.

29
30 Next, to determine transcriptome-wide concordance of ketamine-induced gene expression responses across all
31 comparisons, we evaluated the correlation coefficients between \log_2 fold-change values across the entire transcriptome as
32 a measure of replication. For comparative purposes, we used only genes that were in common with pass filter genes in the
33 current study (12040 genes in common for Ho, et al., and 13532 genes in common for Cathomas, et al.)

34 35 **Weighted gene co-expression network analysis**

36
37 Weighted gene co-expression network analysis (WGCNA) (Langfelder & Horvath, 2008) was performed on the VOOM
38 normalized expression matrix of 17,218 genes across all timepoints jointly. The co-expression similarity matrix was
39 generated; a soft thresholding power of 11 was selected to be applied to the co-expression similarity matrix to calculate
40 adjacencies. The signed (values ranging from -1 to 1) adjacency matrix was then used to determine similarity — or
41 overlap — by generating the Topological Overlap Matrix (TOM). The gene dendrogram was generated by performing
42 average linkage hierarchical clustering on the gene expression dissimilarities ($1 - \text{TOMsimilarity}$), so that the distance
43 between any two groups was defined as the average of all pair-wise distances of the genes within those two groups. Both
44 hybrid and dynamic cuts were plotted to determine the best method for identifying gene clusters. Ultimately, the gene
45 dendrogram was generated using a cut height of 0.9999999999, and modules were identified using the dynamic cut
46 method with a deep split value of 1, with a minimum cluster size (number of genes in the module) of 50. A resulting 34
47 gene modules were identified for downstream analysis.

48
49 Each module's first principal component was used to calculate the module eigengene — a single value summarizing a
50 modules' gene expression. The Pearson's correlations between module eigengenes (MEs) and several subject and sample
51 traits were calculated, including: subject sex, subject mutational class (Class I or Class II), sample timepoint (defined as a
52 factor with levels: Baseline, Post-infusion, Day 1, Week 1, Week 2, Week 4), and sample cell type composition (defined
53 as a continuous variable for the percent composition of each of the identified cell types). In addition to using embedded
54 WGCNA tools to determine whether modules were significantly associated with time, a Dunnett's test was also run on the
55 module MEs to see whether any modules were significantly different between timepoint comparisons.

56 57 **Functional annotation of differentially expressed genes and co-expression modules**

58
59 Functional annotation of identified DEGs and co-expression modules was run using the online portal offered by
60 ToppGene (<https://toppgene.cchmc.org>). For each of the five timepoint comparisons, two DEG lists were generated (one
61 of significant upregulated genes and one of significant downregulated genes, as described in 2.3). These lists were then
62 submitted as the Training set for ToppGene: Candidate gene prioritization. Training parameters were set for: 1) FDR
63 correction, 2) a p-value (determined by the probability density function) cutoff of 0.05, 3) gene limits $1 \leq n \leq 2000$. Test
64 parameters were set for a random sampling size of 5000, and a minimum feature count of 2. ToppGene IDs from the
65 following selected features: GO: Molecular Function, GO: Biological Process, GO: Cellular Component, Human
66 Phenotype, Pathway, Gene Family, Drug, and Disease were used downstream for REVIGO analysis (<http://revigo.irb.hr>).

67
68 Protein-protein interactions were obtained from the STRING database (Szklarczyk et al., 2019) with a signature query of
69 gene co-expression modules identified from our analysis. STRING implements a scoring scheme to report the confidence
70 level for each direct protein-protein interaction (low confidence: < 0.4 ; medium: $0.4 - 0.7$; high: > 0.7). We used a
71 combined STRING score of > 0.4 . Hub genes within the protein-protein interaction network is defined as genes with the
72 highest degree of network connections.

73 *Enrichment analysis of targeted gene sets within co-expression modules*

74
75 All co-expression modules identified by WGCNA analysis were tested for targeted gene set enrichment using
76 GeneOverlap (Shen, 2022). This function uses a Fisher's exact test and an estimated odds-ratio for all pair-wise tests
77 based on a background set of genes detected in the current study. Enrichment was queried for the following targeted gene
78 sets: 1) significant DEGs observed in the current study; 2) curated lists of ASD risk genes taken from two
79 published reports (Satterstrom et al., 2020 & Fu et al., 2022); and 3) curated list of ADNP-interacting or -associated genes
80 based on multiple lines of independent evidence (BioGRID (<https://www.pathwaycommons.org>), SFARI
81 (<https://gene.sfari.org>), and INNATEDB (Lynn, et al., 2008; Breuer, et al., 2013; Lynn, et al., 2010)).

82 **RESULTS**

83 *ADNP allele-specific expression patterns*

84
85
86 The present cohort is comprised of 10 children with ADNP syndrome (7 male, 3 female) (**Supplemental Table 1**). The
87 peripheral blood transcriptome was systematically profiled at six distinct timepoints for each participant (**Figure 1A**).
88 Participants harbored nine unique pathogenic variants within *ADNP*, thereby capturing the genetic heterogeneity
89 associated with this syndrome (**Figure 1B**). Among these variants, six were classified as frameshift mutations, and three
90 were identified as nonsense mutations, with two participants exhibiting the recurrent p.Tyr719* variant.

91
92 While *ADNP* mutations have been thought to result in haploinsufficiency, recent investigations have revealed that mutant
93 *ADNP* alleles are not subject to nonsense-mediated decay and are associated with distinct methylation changes in blood.
94 Thus, for each participant in this cohort, we performed a targeted analysis and queried the expression of *ADNP* mutant
95 and reference (healthy) alleles (*see Materials and Methods*). Presence of *ADNP* mutant allele was confirmed in 9 out of
96 10 participants, whereby reference alleles ranged from 49%-83% of total *ADNP* expression (mean 61%; **Figure 1B**).
97 Notably, the ratio of reference over mutant allele expression for *ADNP* remained consistent throughout the entire trial
98 across all participants (**Supplemental Figure 1A, Supplemental Table 1**). Likewise, the gene expression profile for
99 *ADNP* mRNA did not exhibit statistically significant changes in response to ketamine treatment, nor did the expression of
100 other known ASD-related genes (**Supplemental Figure 1B & 1C**).

101 *Early immediate transcriptomic response to ketamine treatment*

102
103
104 To comprehensively assess the transcriptome-wide effects of ketamine treatment, we first evaluated the impact of various
105 factors on gene expression profiles. For each gene, a linear mixed model was employed to determine the proportion of
106 gene expression variation attributable to different biological and technical covariates (**Supplemental Figure 2**).
107 Collectively, these covariates accounted for approximately 48% of the mean transcriptome variation. Among them, donor
108 treated as a repeated measure exerted the most substantial genome-wide effect, explaining a median of 28% of the
109 observed variation. Additionally, timepoint and RNA integrity numbers (RIN) contributed to transcriptome variability,
110 explaining approximately 3.7% and 2.7%, respectively. The remaining factors accounted for less than 1% of the overall
111 transcriptome variability. Subsequently, to determine differential gene expression, we conducted an analysis comparing
112 gene expression levels at each timepoint to the baseline, while accounting for potential confounding effects of donor as a
113 repeated measure, RIN, and biological sex. This analysis identified ketamine-induced differentially expressed genes
114 (DEGs; FDR < 5%): 1325 DEGs at post-infusion (689 upregulated, 636 downregulated); 776 DEGs at day 1 (227
115 upregulated, 549 downregulated); 122 DEGs at week 2 (18 upregulated, 104 downregulated); 80 DEGs at week 4 (10
116 upregulated, 70 downregulated) (**Figure 2A, Supplemental Table 2**). No significant DEGs were identified at week 1.
117 Overall, the strongest transcriptional effect was observed immediately after ketamine treatment at the post-infusion

18 timepoint (**Figure 2B**), and most of these genes were not dysregulated at later timepoints (**Supplemental Figure 3**),
19 indicating that their expression patterns resumed baseline expression levels one day later.

21 *Post-infusion differential expression is explained by monocyte-specific gene signatures*

23 Cell type proportions were included as covariates into our linear models to gauge their influence on differential gene
24 expression signatures. We observed pronounced differences on the post-infusion DEG signature when accounting for
25 monocytes (**Figure 2C**), which contributed to more than 98% of the observed DEG profile. Notably, the estimated
26 proportion of circulating monocytes significantly decreased post-infusion (Dunnett's test, p -value= 0.047, ~4.5% change),
27 whereas the estimated frequencies for all other cell types were stable and did not change over the time course
28 (**Supplemental Figure 4, Supplemental Table 2**). Next, to support this observation, we queried the expression of the
29 post-infusion DEGs within thousands of single peripheral blood mononuclear cells across two independent scRNA-seq
30 experiments (*see Methods*). These analyses confirmed that post-infusion DEGs are preferentially and highly expressed in
31 CD14+ monocytes (**Supplemental Figure 5**). Importantly, such enrichment was not observed in other cell type
32 populations, nor for any other DEG signature from other timepoints, suggesting that acute effects of ketamine may perturb
33 monocyte-specific gene expression.

35 *Replicating ketamine-induced gene expression profiles in independent transcriptomic studies*

37 To validate the observed ketamine-induced gene expression signatures, we turned to two independent transcriptomic
38 studies that investigate the impact of ketamine. In the first study, the HMC3 human microglial cell line was used to
39 examine the effect of ketamine or ketamine with estradiol (E2) relative to vehicle conditions. The second study explored
40 the impact of intravenous ketamine (0.5mg/kg) on the peripheral blood transcriptome of individuals with treatment
41 resistant depression, specifically at 24 hours post-treatment, relative to an untreated baseline timepoint. To ensure
42 accuracy and comparability, all data from these studies were downloaded, re-processed and analyzed using the same
43 methodology (*see Methods*). To determine replication of ketamine-induced transcriptomic signatures, we evaluated the
44 transcriptome-wide concordance of ketamine-induced log₂ fold-changes across all comparisons in the current study
45 alongside the findings from the two independent reports (**Figure 2D**). Encouragingly, a high level of concordance was
46 observed across the different time points in the current study. Notably, the post-infusion timepoint exhibited substantial
47 transcriptome-wide concordance not only with ketamine-induced effects in microglia (ketamine, $R=0.48$; ketamine+E2
48 $R=0.54$) (**Figure 2E**), but also with ketamine-induced effects in peripheral blood ($R=0.35$) (**Figure 2F**). These results
49 indicate that the early immediate transcriptomic response to ketamine that we observed in ADNP syndrome replicate
50 across different studies and models.

52 *Co-expression network analysis informs ketamine-induced gene networks*

54 To gain further biological insights to the ketamine-induced gene expression patterns, we employed WGCNA. This
55 approach aggregates gene expression variation into discrete co-expression modules across. Through this analysis, we
56 identified 34 co-expression modules (**Figure 3A; Supplemental Table 3**) varying in size from 51 to 1356 genes. Of these
57 modules, six exhibited significant changes in expression levels relative to baseline at one or more subsequent time points
58 (Dunnett's test, $p < 0.05$) (**Figure 3B**). For instance, modules M1 (232 genes) and M2 (735 genes) displayed significant
59 down-regulation post-infusion compared to baseline ($p=1.93 \times 10^{-8}$, $p=5.20 \times 10^{-70}$, respectively) and these modules were
60 strongly enriched for functions related to mRNA processing and RNA metabolism (**Figure 3C**). Conversely, modules M3
61 (96 genes) and M4 (1040 genes) were significantly up-regulated at post-infusion relative to baseline ($p=5.45 \times 10^{-24}$,
62 $p=3.01 \times 10^{-93}$, respectively). Module M4 was significantly enriched for immune and inflammatory responses and MAPK
63 cascades (**Figure 3C, Supplemental Figure 6A**). In addition, down-regulation of module M5 (557 genes) at day 1
64 ($p=7.15 \times 10^{-95}$) was observed and enriched for processes in the blood and cellular components such as platelets and

55 plasma, as well as processes involving myeloid cells (**Supplemental Figure 6B**). Finally, up-regulation of module M6 (55
56 genes) was observed post-infusion and day 1 ($p=7.82 \times 10^{-11}$, $p=3.73 \times 10^{-2}$, respectively), however did not show significant
57 functional annotation.

58
59 To further explore the potential involvement of ASD risk genes, we curated well-known lists of ASD-associated genes
60 and examined their co-expression and dynamic ketamine-induced transcriptional responses in peripheral blood. However,
61 no significant enrichment was observed, aligning with our previous analysis (**Supplemental Figure 7**). Notably, we also
62 did not observe enrichment for curated lists of ADNP interacting genes within any co-expression modules in the current
63 study (**Supplemental Figure 7**). Overall, these findings indicate that ketamine treatment exerts a transient effect
64 characterized by the up-regulation of inflammatory responses and the down-regulation of RNA processes, which quickly
65 return to baseline levels within one day. These responses do not include ADNP nor a significant proportion of other ASD
66 risk genes.

67 **DISCUSSION**

68
69 This study investigated the transcriptomic response to ketamine treatment in children with ADNP syndrome, a monogenic
70 neurodevelopmental disorder associated with ASD. Our findings contribute to the understanding of ketamine's effects on
71 gene expression and provide insights into potential therapeutic mechanisms for ketamine on behavioral health and on
72 ADNP syndrome. We explore three therapeutic mechanisms for ketamine including one hypothesis-driven and two
73 unbiased approaches: (1) effects of ketamine on the expression of ADNP and other ASD-associated genes; (2) acute
74 effects of ketamine on transcriptome-wide and gene module expression; and (3) persistent effects of ketamine on
75 transcriptome-wide and gene module expression.

76
77 One mechanism we exclude is a direct effect of ketamine treatment on the expression levels of *ADNP* or other known
78 ASD-related genes. This observation aligns with independent investigations that also show limited alterations in ASD-
79 related gene expression following ketamine administration (Ho, et al., 2019; Cathomas, et al. 2021). As such, clinical
80 benefits observed with ketamine are likely mediated by broader downstream effects of ketamine, such as modulation of
81 synaptic plasticity, glutamate signaling, or neuroinflammatory responses (Nugent, et al., 2019; Kopelman, et al., 2023;
82 Abdallah, et al., 2018; Li, et al., 2020; Chen, et al., 2021; Grieco, et al., 2021; Chen, et al., 2018).

83
84 The transcriptome-wide response to ketamine treatment exhibited dynamic patterns across different timepoints, providing
85 valuable insights into the temporal dynamics of ketamine-induced gene expression changes. The most pronounced
86 transcriptional effect was observed immediately following ketamine infusion, characterized by a substantial number of
87 DEGs. However, most of these genes returned to baseline expression levels within one day, providing the opportunity to
88 examine acute and persistent effects of ketamine on gene expression. The acute findings are in line with previous research
89 highlighting the acute and short-lasting effects of ketamine on neuronal activity and synaptic plasticity (Kim, et al., 2022;
90 Chen, et al., 2021; Li, et al., 2010; Kopelman, et al., 2023; Grieco, et al., 2021). The rapid normalization of gene
91 expression suggests that ketamine-induced alterations in transcription are part of a dynamic and regulated process,
92 potentially involving the transient modulation of signaling pathways or feedback mechanisms. By integrating estimated
93 cell-type compositions, our analysis revealed that the post-infusion DEG signature was primarily driven by changes in
94 monocyte-specific gene expression. Monocytes, as immune cells involved in inflammatory responses, play crucial roles in
95 shaping the immune milieu within the central nervous system (Peng, et al., 2022; Arteaga-Henríquez, et al., 2022; Xie, et
96 al., 2017). The upregulation of genes associated with immune and inflammatory processes observed in our study aligns
97 with previous evidence highlighting the involvement of the immune system in the pathophysiology of
98 neurodevelopmental disorders, including ASD (Arteaga-Henríquez, et al., 2022; Molloy, et al., 2005; Gupta, et al., 1998;
99 Dantzer, et al., 2008). Moreover, the enrichment of post-infusion DEGs in monocytes, as confirmed by single-cell RNA

sequencing experiments, provides further support for the pivotal role of monocyte-driven transcriptomic alterations in response to ketamine treatment. CD14⁺ monocytes, known as a subset of monocytes with distinct functional properties, have been implicated in neuroinflammation and have been shown to contribute to the pathogenesis of neurodegenerative disorders and psychiatric conditions (Padmos, et al., 2008; Nowak, et al., 2019; Rodríguez, et al., 2017). The preferential expression of ketamine-induced DEGs within CD14⁺ monocytes suggests their active participation in mediating the transcriptomic response to ketamine administration and points towards the potential involvement of neuroinflammatory processes in the therapeutic effects of ketamine.

To validate our findings and assess the generalizability of ketamine-induced gene expression signatures, we compared our acute results with two independent transcriptomic studies investigating the effects of ketamine. Encouragingly, we observed a high level of concordance between the transcriptome-wide effects of ketamine in ADNP syndrome and the effects observed in microglia and peripheral blood of individuals with treatment-resistant depression. This replication across different experimental and clinical models supports the notion that the molecular pathways and mechanisms underlying the therapeutic effects of ketamine exhibit a degree of consistency and universality across various neurological and psychiatric conditions. Microglia, the resident immune cells of the central nervous system, and monocytes, a subset of immune cells found in peripheral blood, share common developmental origins and functional properties. Both cell types play crucial roles in immune responses and inflammation within the brain (Andoh, 2021; Ritzel, et al., 2015). The fact that ketamine-induced gene expression changes in ADNP syndrome show concordance with those observed in microglia and peripheral blood further supports the involvement of immune-related processes in the therapeutic effects of ketamine.

We performed weighted gene co-expression network analysis to further explore the biological processes associated with ketamine treatment in ADNP syndrome. Notably, modules associated with mRNA processing and RNA metabolism exhibited down-regulation, suggesting a potential dampening effect of ketamine on these processes. This observation aligns with previous studies reporting the acute effects of ketamine on neuronal activity and synaptic plasticity, which involve the regulation of RNA processes (Ho, et al., 2019; Kim, et al., 2022; Cathomas, et al., 2022). In contrast, modules related to immune and inflammatory responses displayed significant up-regulation following ketamine treatment. These findings support the notion that ketamine exerts immunomodulatory effects, consistent with emerging evidence indicating the involvement of the immune system in the pathophysiology of neurodevelopmental disorders (Arteaga-Henríquez, et al., 2022; Molloy, et al., 2005; Tanabe, et al., 2018). The up regulation of genes associated with immune and inflammatory processes highlights the potential role of ketamine in modulating inflammatory pathways in ADNP syndrome. Interestingly, the observed changes in gene expression were transient, with most genes returning to baseline expression levels within one day post-infusion. This suggests that ketamine elicits a transient perturbation of molecular pathways, which subsequently return to their basal state. This dynamic response may reflect the rapid adaptation of cellular processes following ketamine administration, potentially involving feedback mechanisms and homeostatic regulation.

Beyond the acute effects, unraveling ketamine's sustained effects on gene expression is crucial for gaining insights into its prolonged therapeutic potential and potential adverse effects, particularly in the context of treating ADNP syndrome, diverse neuropsychiatric disorders, and chronic pain. Towards this end, we noted that ketamine exerted lasting effects on a select set of genes, particularly those encompassed in co-expression module M6 (**Figure 3**). Although the functional annotation of these genes still remains elusive, a number of individual genes with sustained effects were notable. Of special interest are several metabolism-related genes that showed upregulation in response to ketamine. These include genes involved in cellular metabolism (e.g. *NADSYN1*), cholesterol metabolism (e.g. *LCAT* and *SOAT1*), lipid metabolism (e.g. *ACOT8*), and fatty acid metabolism (e.g. *CPT1A*) (Natesan & Kim, 2021). While there isn't a direct established connection with ketamine, the role of cholesterol metabolism and lipid signaling in neurological disorders has been previously indicated, thus making it an intriguing domain for mental health research. Another gene of interest is *SCN9A*, which encodes for a voltage-gated sodium channel involved in pain perception (Cox et al., 2006). Although ketamine is acknowledged for its pain-modulating properties, its association with *SCN9A* remains largely unexplored. Overall, it is

57 vital to continue expanding our knowledge of ketamine's long-term effects on gene expression, a research area that holds
58 promise in improving our understanding of ketamine's complex mechanism of action. This, in turn, will aid in the design
59 and development of newer, more effective, and safer medications derived from or inspired by ketamine.
50

51 It is also important to acknowledge several limitations that should be considered when interpreting the results of this
52 study. Firstly, the sample size of the cohort with ADNP syndrome included in this study was relatively small, which may
53 limit the generalizability of the findings to the broader ADNP syndrome population. Although we were able to
54 demonstrate the generalizability of ketamine-induced transcriptomic signatures across independent studies, future
55 investigations with larger cohorts are needed to validate and expand upon these results. Secondly, it is important to
56 recognize that the effects of ketamine treatment can vary depending on various factors, including individual patient
57 characteristics. Although these factors were held constant in our study, they may influence the observed gene expression
58 changes and should be considered when interpreting the results. Thirdly, while we employed a two-step analytical
59 approach and utilized orthogonal datasets to assess the cellular specificity of the post-infusion DEG signal, further studies
60 focusing on high-dimensional immune profiling or fluorescence-activated cell sorting could provide a more precise
61 measurement of cell type fluctuations following treatment. Lastly, although we employed a rigorous methodology to
62 evaluate the peripheral blood transcriptome, it is essential to acknowledge that blood-based gene expression profiles may
63 not fully capture the complexity of gene expression patterns in specific brain regions or cell types that may be more
64 directly relevant to the pathophysiology of ADNP syndrome. Therefore, caution should be exercised when extrapolating
65 these findings to brain-specific mechanisms.

66 This study provides valuable insights into the transcriptomic response to ketamine treatment in individuals with ADNP
67 syndrome. The dynamic and time-dependent nature of the response highlights the complex molecular mechanisms
68 underlying ketamine's therapeutic actions. The prominent role of monocyte-specific gene expression alterations suggests a
69 potential link between immune and inflammatory processes and the therapeutic effects of ketamine in
70 neurodevelopmental disorders. The down-regulation of mRNA processing and RNA metabolism modules, coupled with
71 the up-regulation of immune and inflammatory response modules, underscores the multifaceted nature of ketamine's
72 molecular effects. These findings deepen our understanding of the intricate pathways affected by ketamine and provide a
73 foundation for future research aimed at unraveling the precise cellular and molecular targets of ketamine treatment.
74 Moving forward, it is essential to conduct further investigations to elucidate the specific molecular pathways and
75 downstream effects of ketamine treatment in ADNP syndrome. Additionally, future research endeavors should encompass
76 larger cohorts, repeated dosing, experimentally tractable neuronal model systems, longer follow-up periods, and diverse
77 populations to validate the generalizability and clinical implications of our findings.

REFERENCES

1. 10x Genomics, 2016. 33k PBMCs from a Healthy Donor (v2), Single Cell Immune Profiling Dataset by Cell Ranger 1.1.0. [Online] [Accessed November 2022].
2. 10x Genomics, 2016. *Fresh 68k PBMCs (Donor A) (v1), Single Cell Immune Profiling Dataset by Cell Ranger 1.1.0.* [Online] Available at: <https://www.10xgenomics.com/resources/datasets/fresh-68k-pbm-cs-donor-a-1-standard-1-1-0> [Accessed November 2022].
3. Abdallah, C.G., et al., 2018. The effects of ketamine on prefrontal glutamate neurotransmission in healthy and depressed subjects. *Neuropsychopharmacol.* 2018 Sep;43(10):2154-2160.
4. Acevedo-Diaz, E. et al., 2020. Comprehensive assessment of side effects associated with a single dose of ketamine in treatment-resistant depression. *Journal of Affective Disorders.* Issue 263, pp. 568-575.
5. Andoh M, & Koyama R., 2021. Comparative Review of Microglia and Monocytes in CNS Phagocytosis. *Cells.* 2021 Sep 27; 10(10):2555.
6. Arteaga-Henríguez G, et al., 2022. Activation of the Monocyte/Macrophage System and Abnormal Blood Levels of Lymphocyte Subpopulations in Individuals with Autism Spectrum Disorder: A Systematic Review and Meta-Analysis. *Int J Mol Sci.* 2022 Nov 18; 23(22):14329.
7. Bend E.G., Aref-Eshghi E., Everman D.B., Rogers R.C., Cathey S.S., Prijoles E.J., Lyons M.J., Davis H., Clarkson K., Gripp K.W. Gene domain-specific DNA methylation epigenatures highlight distinct molecular entities of ADNP syndrome. *Clin. Epigenetics.* 2019;11:64.
8. Bray, N., Pimentel, H. & Melsted, P., 2016. Near-optimal probabilistic RNA-seq quantification. *Nature Biotechnology.* Volume 34, pp. 525-527.
9. Breen, M. S., Fan, X., Levy, T., Pollak, R. M., Collins, B., Osman, A., ... & Phillips, J. M. (2023). Large 22q13. 3 deletions perturb peripheral transcriptomic and metabolomic profiles in Phelan-McDermid syndrome. *Human Genetics and Genomics Advances*, 4(1).
10. Breen, M. S., Garg, P., Tang, L., Mendonca, D., Levy, T., Barbosa, M., ... & De Rubeis, S. (2020). Epigenatures stratifying Helsmoortel-Van Der Aa syndrome show modest correlation with phenotype. *The American Journal of Human Genetics*, 107(3), 555-563.
11. Breuer, et al., 2013. InnateDB: systems biology of innate immunity and beyond - recent updates and continuing curation. *Nucl. Acids Res.* 2013; 41 (D1).
12. Broad Institute, 2019. *Picard Toolkit.* [Online] Available at: <https://broadinstitute.github.io/picard> [Accessed 2022].
13. Cappuyns E., et al., 2018. Mutations in ADNP affect expression and subcellular localization of the protein. *Cell Cycle.* 2018;17(9):1068-1075.

- 38 **14.** Cathomas, F. et al., 2022. Whole blood transcriptional signatures associated with rapid antidepressant response to
39 ketamine in patients with treatment resistant depression. *Translational Psychiatry*. 10 January, 12(1), p. 12.
- 40
- 41 **15.** Chen, B. et al., 2018. Profiling Tumor Infiltrating Immune Cells with CIBERSORT. *Methods Molecular Biology*.
42 Volume 1711, pp. 243-259.
- 43
- 44 **16.** Chen, M., et al., 2018. Rapid inflammation modulation and antidepressant efficacy of a low-dose ketamine
45 infusion in treatment-resistant depression: A randomized, double-blind control study. *Psychiatry Research*,
46 269:207-211.
- 47
- 48 **17.** Chen, M., et al., 2021. Treatment response to low-dose ketamine infusion for treatment-resistant depression: A
49 gene-based genome-wide association study. *Genomics*, 113(2): 507-514.
- 50
- 51 **18.** Cox, James J., Frank Reimann, Adeline K. Nicholas, Gemma Thornton, Emma Roberts, Kelly Springell, Gulshan
52 Karbani et al. "An SCN9A channelopathy causes congenital inability to experience pain." *Nature* 444, no. 7121
53 (2006): 894-898.
- 54
- 55 **19.** Danecek, P., et al., 2021. Twelve years of SAMtools and BCFtools. *GigaScience*, February, 10(2), p. giab008.
- 56
- 57 **20.** Dantzer R., et al., 2008. From inflammation to sickness and depression: when the immune system subjugates the
58 brain. *Nat. Rev. Neuroscience*. 9, 46.
- 59
- 60 **21.** Dobin, A. et al., 2013. STAR: ultrafast universal RNA-seq aligner. *Bioinformatics*, 1 Jan, 29(1), pp. 15-21.
- 61 **22.** Durinck, S. et al., 2005. BioMart and Bioconductor: a powerful link between biological databases and microarray
62 data analysis. *Bioinformatics*, Volume 21, pp. 3439-3440.
- 63 **23.** Fu, J.M., et al., 2022. Rare coding variation provides insight into the genetic architecture and phenotypic context
64 of autism. *Nat Genet*. 54:1320–1331.
- 65
- 66 **24.** Gozes, I., 2020. The ADNP Syndrome and CP201 (NAP) Potential and Hope. *Frontiers in Neurology*, Issue 11, p.
67 608444.
- 68 **25.** Gozes, I. et al., 2017. Premature primary tooth eruption in cognitive/motor-delayed ADNP-mutated children.
69 *Translational psychiatry*, 7(2), p. e1043.
- 70
- 71 **26.** Grieco SF, et al., 2021. Neuregulin signaling mediates the acute and sustained antidepressant effects of
72 subanesthetic ketamine. *Transl Psychiatry*. 2021 Feb 24;11(1):144.
- 73 **27.** Gupta, S., et al., 1998. Th1- and Th2-like cytokines in CD4+ and CD8+ T cells in autism. *Journal of*
74 *Neuroimmunology*, 85(1):106-109.
- 75 **28.** Helmsmoortel, C. et al., 2014. A SWI/SNF-related autism syndrome caused by de novo mutations in ADNP. *Nature*
76 *genetics*, 46(4), pp. 380-384.
- 77
- 78 **29.** Herz J., et al., 2017. Myeloid Cells in the Central Nervous System. *Immunity*. 2017 Jun 20;46(6):943-956.
- 79
- 80 **30.** Hoffman, G. & Schadt, E., 2016. variancePartition: Interpreting drivers of variation in complex gene expression
81 studies. *BMC Bioinformatics*, Volume 17.
- 82
- 83 **31.** Ho, M. et al., 2019. Ketamine and Active Ketamine Metabolites Regulate STAT3 and the Type I Interferon
84 Pathway in Human Microglia: Molecular Mechanisms Linked to the Antidepressant Effects of Ketamine.
85 *Frontiers in Pharmacology*, 5 November, Issue 10, p. 1302.

- 36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
32. Jia, Y. & Hong, J., 2014. Dual Effects of Ketamine: Neurotoxicity Versus Neuroprotection in Anesthesia for the Developing Brain. *Journal of Neurosurgical Anesthesiology*, April, 26(2), pp. 155-160.
 33. Karmon, G. et al., 2022. Novel ADNP Syndrome Mice Reveal Dramatic Sex-Specific Peripheral Gene Expression With Brain Synaptic and Tau Pathologies. *Biological Psychiatry*, 92(1), pp. 81-95.
 34. Kim J., et al., 2022. Transcriptional Activation, Deactivation and Rebound Patterns in Cortex, Hippocampus and Amygdala in Response to Ketamine Infusion in Rats. *Frontiers in Molecular Neuroscience*. 2022 May 30;15:892345.
 35. Kolevzon, A. et al., 2022. An open-label study evaluating the safety, behavioral, and electrophysiological outcomes of low-dose ketamine in children with ADNP syndrome. *Human Genetics and Genomics Advances*, 3(4).
 36. Kopelman, J., et al., 2023. Rapid neuroplasticity changes and response to intravenous ketamine: a randomized controlled trial in treatment-resistant depression. *Transl Psychiatry* 13, 159.
 37. Langfelder, P. & Horvath, S., 2008. WGCNA: an R package for weighted correlation network analysis. *BMC Bioinformatics*, Issue 9, p. 559.
 38. Li, M., et al., 2020. Default mode network connectivity change corresponds to ketamine's delayed glutamatergic effects. *Eur Arch Psychiatry Clin Neurosci* **270**, 207–216.
 39. Liao, Y., Smyth, G. & Shi, W., 2014. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. *Bioinformatics*, 1 April, 30(7), pp. 923-930.
 40. Love, M., Huber, W. & Anders, S., 2014. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biology*, Issue 15, p. 550.
 41. Lynn, et al., 2008. InnateDB: facilitating systems-level analyses of the mammalian innate immune response. *Molecular Systems Biology* 2008; 4:218.
 42. Lynn, et al., 2010. Curating the Innate Immunity Interactome. *BMC Systems Biology* 2010; 4:117.
 43. Molloy, C., et al., 2005. Elevated cytokine levels in children with autism spectrum disorder. *Journal of Neuroimmunology*, Volume 172, Issue 1, 198 – 205.
 44. Natesan, V. and Kim, S.J., 2021. Lipid metabolism, disorders and therapeutic drugs—review. *Biomolecules & therapeutics*, 29(6), p.596.
 45. NIH , 2021. *ADNP syndrome*. [Online] Available at: <https://rarediseases.info.nih.gov/diseases/12931/adnp-syndrome> [Accessed 2022].
 46. Nowak W, et al., 2019. Pro-inflammatory monocyte profile in patients with major depressive disorder and suicide behaviour and how ketamine induces anti-inflammatory M2 macrophages by NMDAR and mTOR. *EBioMedicine*. 2019 Dec;50:290-305.
 47. Nugent, A., et al., 2019. Synaptic potentiation and rapid antidepressant response to ketamine in treatment-resistant major depression: A replication study. *Psychiatry Research: Neuroimaging*. **283**: 64-66,

- 34
35 48. Padmos R., et al., 2008. A Discriminating Messenger RNA Signature for Bipolar Disorder Formed by an Aberrant
36 Expression of Inflammatory Genes in Monocytes. *Arch Gen Psychiatry*.2008;65(4):395–407.
- 37 49. Peng J, et al., 2022. Monocytes maintain central nervous system homeostasis following helminth-induced
38 inflammation. *Proc Natl Acad Sci U S A*. 2022 Sep 13;119(37):e2201645119.
- 39
40 50. Ritchie, M. et al., 2015. limma powers differential expression analyses for RNA-sequencing and microarray
41 studies. *Nucleic Acids Research*, 43(7), p. e47.
- 42
43 51. Ritzel R., et al., 2015. Functional differences between microglia and monocytes after ischemic stroke. *J*
44 *Neuroinflammation*. 2015 May 29;12:106.
- 45
46 52. Robinson, M., McCarthy, D. & Smyth, G., 2010. edgeR: a Bioconductor package for differential expression
47 analysis of digital gene expression data. *Bioinformatics*, 26(1), pp. 139-140.
- 48
49 53. Rodríguez, N., et al., 2017. Inflammatory dysregulation of monocytes in pediatric patients with obsessive-
50 compulsive disorder. *J Neuroinflammation* **14**, 261.
- 51
52 54. Searles Quick, VB, et al., 2021. Leveraging large genomic datasets to illuminate the pathobiology of autism
53 spectrum disorders. *Neuropsychopharmacology*. 2021 Jan;46(1):55-69.
- 54
55 55. Shen, L., 2022. *GeneOverlap: Test and visualize gene overlaps. R package version 1.34.0*. [Online] Available at:
56 <http://shenlab-sinai.github.io/shenlab-sinai/> [Accessed 2022].
- 57
58 56. Signorell, A. & et al, 2022. *DescTools: Tools for descriptive statistics. R package version 0.99.47.*, s.l.: s.n.
- 59
60 57. Siper, P. et al., 2021. Sensory Reactivity Symptoms Are a Core Feature of ADNP Syndrome Irrespective of
61 Autism Diagnosis. *Genes (Basel)*, 27 Feb, 12(3), p. 351.
- 62
63 58. SourceForge, 2009. *SAMtools*. [Online] Available at: <https://samtools.sourceforge.net/cns0.shtml> [Accessed 31
64 Jan 2023].
- 65
66 59. Szklarczyk, Damian, et al. "STRING v11: protein–protein association networks with increased coverage,
67 supporting functional discovery in genome-wide experimental datasets." *Nucleic acids research* 47.D1 (2019):
68 D607-D613.
- 69
70 60. Tanabe S. & Yamashita T., 2018. The role of immune cells in brain development and neurodevelopmental
71 diseases. *Int Immunol*. 2018 Sep 25;30(10):437-444.
- 72
73 61. Van Dijck, A. et al., 2019. Clinical Presentation of a Complex Neurodevelopmental Disorder Caused by
74 Mutations in ADNP. *Biological Psychiatry*, 85(4), pp. 287-297.
- 75
76 62. Wang, L., Wang, S. & Li, W., 2012. RSeQC: quality control of RNA-seq experiments. *Bioinformatics*, 28(16),
77 pp. 2184-2185.
- 78
79 63. Xie, X., et al., 2017. Monocytes, microglia, and CD200-CD200R1 signaling are essential in the transmission of
80 inflammation from the periphery to the central nervous system. *J. Neurochem.*, 141: 222-235.
- 81

- 32 **64.** Zarate, C. et al., 2012. Relationship of ketamine's plasma metabolites with response, diagnosis, and side effects in
33 major depression. *Biological Psychiatry*, 72(4), pp. 331-338.
- 34
- 35 **65.** Zheng, G., Terry, J. & Belgrader, P., 2017. Massively parallel digital transcriptional profiling of single cells.
36 *Nature Communications*, Volume 8, p. 14049.
- 37
- 38

39

40 **Acknowledgements**

41

42 We are extremely grateful to the families who participated and to the ADNP Kids Research Foundation and
43 the Foundation for Mood Disorders for their support. Support for mediKanren was provided by the National Center for
44 Advancing Translational Sciences, National Institutes of Health, through the Biomedical Data Translator Program,
45 awards [OT2TR003435](#) and [OT2TR002517](#). Any opinions expressed in this document are those of the Translator
46 community at large and do not necessarily reflect the views of NCATS, individual Translator team members, or affiliated
47 organizations and institutions. ClinicalTrials.gov Identifier: [NCT04388774](#), Low-Dose Ketamine in Children with ADNP
48 Syndrome, <https://clinicaltrials.gov/ct2/show/NCT04388774>.

49

50 **Data and code availability**

51

52 RNA-sequencing fastq files have been deposited in the Gene Expression Omnibus under accession number GSEXXXXX
53 (data will be uploaded prior to date of publication). Computational code and intermediate data files required for
54 reproducibility of these results is available on GitHub (<https://github.com/buxgrice/adnpket>).

55

56 **Ethics and approval to participate.**

57 All study participants have given written informed consent, and the genetic study has been approved by the Icahn School
58 of Medicine at Mount Sinai Institutional Review Board.

59 **Competing interests**

60

61 Alexander Kolevzon is on the scientific advisory boards of Ovid Therapeutics, Ritrova Therapeutics, and Jaguar
62 Therapeutics and consults to Acadia, Alkermes, GW Pharmaceuticals, Neuren Pharmaceuticals, Clinilabs Drug
63 Development Corporation, and Scioto Biosciences. Joseph D. Buxbaum consults for BridgeBio Pharma. The remainder of
64 the authors declare no competing interests.

65

66

67

18
19 **MAIN FIGURE LEGENDS**

20
21 **Figure 1. Trial design and ADNP allele-specific expression.** (A) Clinical trial workflow and data collected across the
22 time course. A total of 10 pediatric participants were enrolled in the trial and were screened within 28 days of the trial
23 onset. Post-infusion represents the same day as intravenous ketamine treatment (0.5 mg/kg, over 40 minutes), while Day
24 1 is the following day. (B) Pathogenic variants represented by the study cohort and their locations along the ADNP gene
25 locus. Two patients had recurrent p.Tyr719* mutations. ADNP RNA-seq read pileups were queried for each mutation
26 (57.66 ± 22.35 read coverage). The percent of ADNP reference (healthy) allele at baseline (or at 4 weeks, if baseline
27 measurements were not available) are in grey, while the percent of ADNP mutant allele is in red.

28
29 **Figure 2. Ketamine-induced gene expression perturbations in peripheral blood cells.** (A) The number of
30 differentially expressed genes (DEGs) passing $FDR < 5\%$ (x-axis) at each timepoint compared to baseline (y-axis).
31 Upregulated genes are shown in red and downregulated genes are shown in blue. (B) Volcano plot (x-axis: \log_2FC , y-axis:
32 $-\log_{10}(p.adj)$) illustrating DEGs identified in the baseline vs. post-infusion comparison, with colored points representing
33 genes passing $FDR < 5\%$. (C) Heatmap of DEGs shared before and after covarying for cell type (y-axis) at each timepoint
34 comparison (x-axis). Covarying for monocytes showed the strongest effect when comparing baseline and post-infusion,
35 accounting for more than 98% of the observed DEG signal. (D) Correlation plot of transcriptome-wide \log_2 fold-changes
36 of differentially expressed genes identified at each timepoint, compared to results from a study in immortalized microglia
37 (Ho et al.) (*Microglia: Ketamine*, ketamine vs. vehicle; *Microglia: Ketamine + E2*, ketamine and estradiol vs. vehicle)
38 and a study of baseline vs. post-treatment expression in a cohort of individuals with treatment-resistant depression
39 (Cathomas et al.) (*PBMCs: Ketamine*). Circle size and color (scaled from 0-1) represent correlation strength. Density plots
40 comparing baseline vs. post-infusion from the current study (x-axis) relative to (E) findings from microglia treated with
41 ketamine (left) and ketamine + estradiol [E2] (right) (y-axis) and relative to (F) PBMCs from individuals treated with a
42 single-low dose ketamine infusion (y-axis). R values of the lm fit values are indicated above the regression lines. PMIDs
43 are provided for each independent study, respectively.

44
45 **Figure 3. Ketamine-induced changes in gene co-expression patterns.** (A) Gene dendrogram (top) of WCGNA analysis
46 applied to the VROOM normalized expression matrix of 17,218 genes across all timepoints jointly. A total of 34 co-
47 expression modules were identified using the dynamic split method colored (upper bar). Each line on the dendrogram
48 represents a single gene. Color bars indicate the association of each gene with the respective timepoint (negative
49 correlations in blue, positive correlations in red). (B) Boxplots of the ME values (y-axis) of the six modules showing
50 significant association (Dunnnett's test, $p < 0.05$) with time at one or more timepoints (x-axis). (C & D) GO Functional
51 enrichment plots of the purple (M2; left) and yellow (M4; right) modules, which reflect the two modules with the
52 strongest signal for functional enrichment. Bar color indicates GO functional group, and each bar is labelled with the
53 associated enrichment term. Top significant terms are shown for each functional group, with the $-\log_{10}$ of the multiple test
54 corrected p-values (x-axis) shown for each enrichment term (y-axis).

A Open-label study of evaluating longitudinal transcriptional effects of ketamine in ADNP syndrome (n=10)





